RE:RE:RE:RE:RE:biogen suffering ? I hope she leverages the modest benefit of lecanemab into a promotional strategy that stresses PMN310s differences rather than similarities. It's almost October, the baseball analogies practically write themselves. Lecanemab is a longer pop fly than Aducanumab, but they're both outs. Credit the player with making contact as opposed to all the earlier whiffs, but outs are still how you lose.